Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Ret Proto-Oncogene anticorps (AA 896-1063)

RET Reactivité: Humain WB, ELISA Hôte: Souris Monoclonal 8D10C9 unconjugated
N° du produit ABIN966961
  • Antigène Voir toutes Ret Proto-Oncogene (RET) Anticorps
    Ret Proto-Oncogene (RET)
    Épitope
    • 27
    • 21
    • 15
    • 15
    • 15
    • 11
    • 9
    • 9
    • 8
    • 8
    • 8
    • 7
    • 6
    • 6
    • 4
    • 4
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 896-1063
    Reactivité
    • 163
    • 100
    • 81
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain
    Hôte
    • 186
    • 22
    • 2
    • 1
    • 1
    • 1
    Souris
    Clonalité
    • 181
    • 32
    Monoclonal
    Conjugué
    • 90
    • 14
    • 10
    • 9
    • 9
    • 9
    • 9
    • 9
    • 9
    • 9
    • 6
    • 5
    • 5
    • 5
    • 5
    • 5
    • 4
    • 1
    Cet anticorp Ret Proto-Oncogene est non-conjugé
    Application
    • 171
    • 82
    • 66
    • 65
    • 43
    • 28
    • 18
    • 16
    • 15
    • 10
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA
    Purification
    Ascitic fluid
    Immunogène
    Purified recombinant fragment of RET (aa896-1063) expressed in E. Coli.
    Clone
    8D10C9
    Isotype
    IgG1
    Top Product
    Discover our top product RET Anticorps primaire
  • Indications d'application
    Western Bloting: 1/500 - 1/2000.
    ELISA: Propose dilution 1/10000.
    Not yet tested in other applications.
    Determining optimal working dilutions by titration test.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C
  • Antigène
    Ret Proto-Oncogene (RET)
    Autre désignation
    RET (RET Produits)
    Synonymes
    anticorps c-ret, anticorps cret, anticorps etID315074.13, anticorps ret1, anticorps wu:fd13h01, anticorps X-ret, anticorps ret-A, anticorps xret, anticorps RET, anticorps MTC1, anticorps CDHF12, anticorps CDHR16, anticorps HSCR1, anticorps MEN2A, anticorps MEN2B, anticorps PTC, anticorps RET-ELE1, anticorps RET51, anticorps RET9, anticorps c-Ret, anticorps ret proto-oncogene receptor tyrosine kinase, anticorps ret proto-oncogene S homeolog, anticorps ret proto-oncogene, anticorps ret, anticorps ret.S, anticorps RET, anticorps Ret
    Sujet
    RET (ret proto-oncogene) is a member of the cadherin superfamily and a receptor tyrosine kinase, which are cellsurface molecules that transduce signals for cell growth and differentiation. It can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Ligands that bind the Ret receptor include the glial cell line-derived neurotropic factor (GDNF) and its congeners neurturin, persephin and artemin. Alterations in the corresponding Ret gene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma and a congenital developmental disorder known as Hirschsprung's disease. The Tyr905 residue located in the Ret kinase domain plays a crucial role in Ret catalytic and biological activity. Substitution of Phe for Tyr905 dramatically inhibits Ret autophosphorylation activity.
    Synonyms: RET
    ID gène
    5979
    Pathways
    Signalisation RTK, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation
Vous êtes ici:
Support technique